Program Overview

When What We Do Is Not Enough to Treat Infections:
How and Why to Utilize Procalcitonin

The Hospital Quality Foundation, CE Symmetry, and CMEsolutions are excited to provide this innovative, accredited educational activity series on the use of procalcitonin.  

Accessible for all registered learners, the educational content provided within is an up-to-date discussion on procalcitonin biomarker assays and how it can help guide patient management. 

Procalcitonin (PCT) is a biomarker widely used to assess the risk of bacterial infection and to aid in antibiotic stewardship in patients with lower respiratory tract infections (LRTI) and sepsis.

PCT now also demonstrates evolving evidence as a valuable tool in current COVID-19 epidemics to aid in early identification of patients at low risk of bacterial infection on admission as well as assist in detection of bacterial co-infection in hospitalized patients.

We are fortunate to be joined in this discussion by Dr. Jim Neuenschwander, Dr. Michael Broyles, and Dr. Eric Gluck.

The unique perspectives provided by our faculty include lab, pharmacy, critical care, hospital, and emergency medicine. 

The panel explores the economics of procalcitonin and how it can improve practice behavior and patient outcomes.

Please complete the brief registration form and allow yourself the time to be educated and entertained as we take a tour of how procalcitonin can be used in the management of lower respiratory tract infections, COVID-19, predicting and treating sepsis, and antimicrobial stewardship.